Investor Relations

NEWS UPDATE: Veracyte announces definitive agreement to acquire C2i Genomics Read More

Our vision is to transform cancer care for patients all over the world

Veracyte is a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. With our high-performing diagnostic tests, we help patients avoid unnecessary procedures and speed time to diagnosis and appropriate treatments for challenging diseases. These include thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases.

Presentations & Reports

View All

Events

Upcoming

45th Annual Raymond James Institutional Investor Conference

View All